“rare-disease” Archives

in
Entry Author Date Location
Chiesi Licenses Bioasis Tech to Tackle Brain Symptoms of Rare Diseases 07/01/20 Boston
Viela Bio Gets FDA Green Light for Rare Autoimmune Disease Treatment 06/12/20 National
Reata Bags $350M as It Preps Rare Chronic Kidney Disease Drug for FDA 06/11/20 Texas
PTC Therapeutics to Acquire Censa Pharma for Mid-Stage Rare Disease Drug 05/07/20 New York
RDMD Lands $14M to Expand Reach of Rare Disease Research Platform 04/16/20 San Francisco
Blackstone Pays Alnylam $1B to Grab a Stake in RNAi Drug Inclisiran 04/13/20 Boston
Rubius Drops Rare Diseases, Turns to Cancer and Autoimmune Disorders 03/12/20 Boston
Insmed Drug for Rare Pulmonary Disorder Meets Phase 2 Goals 02/03/20 New York
Perceptive Unveils New $210M Fund to Invest in Early-Stage Biotechs 12/10/19 New York
Astellas Bets On Gene Therapy With $3B Audentes Acquisition Offer 12/03/19 National
Emtora Biosciences Turns Sights on Rare Genetic Disease, New Funding 04/30/19 Texas
Rare-Disease Hackathon Leads to $3M for Health Data Startup RDMD 08/20/18 San Francisco
EU Regulators Approve Akcea’s Inotersen. FDA Decisions Are Next. 07/11/18 Boston
Bio Roundup: Hope for Lungs, Bradner’s Complaint, FDA Nods & More 04/20/18 National
Bio Roundup: Trump Health, Cholesterol Wars, 23andMe OK & More 03/09/18 National
Bio Roundup: Nobel Pursuit, Fundraising Fruit, A Rhythmic IPO & More 10/06/17 National
Amicus’s Scioderm Deal Flops as Skin Drug Fails in Phase 3 09/13/17 New York
Bio Roundup: Senate Drama, A.I. Stories, Data Dives, Shkreli & More 06/30/17 National
Synlogic and Its Modified Bacteria Take Over Dying Company, Go Public 05/16/17 Boston
FDA Approves BioMarin Drug, A First for Rare Genetic Batten Disease 04/27/17 San Francisco
Ionis Pharma Spins Out Lipid Disorder Unit Akcea with Plans for IPO 03/27/17 Boston
Often Advocates Of Faster FDA, Patient Groups Wary Of Trump Deregulation 02/10/17 National
Notes From The JPM ’17 Vortex: Trump, Rainstorms & The Price You Pay 01/13/17 National
Amicus Takes Aim at Rare Brain Disorder with MiaMed Acquisition 07/06/16 New York
Inhaled-Drug Maker Savara Buys European Biotech With Two Candidates 06/21/16 Texas
Ra Pharma Gets $58.5M in Crossover Cash to Target Rare Blood Disease 07/23/15 Boston
Horizon Pays $1.1 Billion for Hyperion’s Rare Disease Drugs 03/30/15 San Francisco
With $2M Seed, Perlstein Lab Tests Unorthodox Rare-Disease Plan 07/31/14 San Francisco
West Coast Biotech Roundup: Genentech, CareDx, and More 07/17/14 San Diego
With $22M, True North Points Toward Rare-Disease Clinical Trials 06/17/14 San Francisco
Page 1 of 1